HOOK General/Rough Short Position Analysis
Overall:
* Negative EPS
* June 7th conference Asco will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.
* Negative EPS
* June 7th conference Asco will most likely lead to a double-top.
* The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower.
* Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。